Clinical Trial Update: Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update notes a completed Phase 2/Phase 3 study evaluating combination chemotherapy with or without gemtuzumab ozogamicin or tipifarnib in pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Tipifarnib (tipifarnib)

Snippet

Sponsor: The University of New South Wales | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 2, Phase 3 | Status: COMPLETED